Sanofi GCVRZ 深 滬
已收盤 03-26 16:00:00 美东时间
0.8711
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 總市值 1113.52亿
- 52周最高 0.882
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 總股本 1278.30亿
- 歷史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.153
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints
On Tuesday, Sanofi SA (NASDAQ:SNY) reported data from the Phase 3 Baby-COMET study of Nexviazyme (avalglucosidase alfa). Read Also: EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims Phase 3 Trial Hits Primary And Secondary Endpoints The trial showed that Nexviazyme...
07-01 01:47
UPDATE 3-US FDA declines to approve Unicycive's kidney disease drug
UPDATE 3-US FDA declines to approve Unicycive's kidney disease drug Updates shares, adds analyst comment in paragraph 6 By Padmanabhan Ananthan June 30 (Reuters) - Unicycive Therapeutics UNCY.O said on Tuesday the U.S. drug regulator has declined to approve its drug to treat elevated phosphate level
06-30 19:26
药物受理最新动态：Sanofi-Aventis Recherche & DéveloppementRilzabrutinib片进口申请获受理
国家药品监督管理局药品审评中心数据显示，2026年6月30日，Sanofi-Aventis Recherche & Développement的Ril...
06-30 18:15
Sanofi's Nexviazyme hits primary goal in Pompe disease study
Sanofi (SNY) said Tuesday that Nexviazyme met its primary endpoint in a phase 3 study of treatment-naïve infants six months of age and younger with infantile-onset Pompe disease, with participants ali...
06-30 13:21
Sanofi says Nexviazyme meets endpoints in phase 3 infantile-onset Pompe study
Sanofi says Nexviazyme meets endpoints in phase 3 infantile-onset Pompe study Sanofi reported positive Phase 3 Baby-COMET results for Nexviazyme in treatment-naïve infants with infantile-onset Pompe disease. Data will be presented on July 8, 2026, at the International Congress on Neuromuscular Disea
06-30 13:00
Sanofi Consumer Healthcare India Names PwC as New Statutory Auditor
Sanofi Consumer Healthcare India Limited ( ($IN:SANOFICONR) ) just unveiled an ...
06-30 01:26
EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims
The European Commission has launched a formal antitrust investigation into Sanofi (NASDAQ:SNY) to determine whether the French drugmaker violated EU competition rules through a communication campaign targeting a competing influenza vaccine. The probe centers on allegations that Sanofi disseminated m...
06-27 01:15
Sanofi investigated by EU over alleged flu vaccine disparagement
The European Commission has opened a formal antitrust investigation to assess whether Sanofi (SNY) has breached EU competition rules by carrying out a communication campaign that disparages the only r...
06-26 18:10
MapLight Therapeutics Announces Changes to Board of Directors
MapLight Therapeutics announced the appointment of Martin Babler and Troy Cox to its Board of Directors, succeeding Robert Malenka and Jim Trenkle. Babler joins the Audit Committee, while Cox becomes Chair of the Nominating and Corporate Governance Committee. Both bring extensive experience in biotechnology leadership. Babler previously led Alumis Inc., Principia Biopharma Inc., and Talima Therapeutics, Inc., while Cox served as CEO of Foundation...
06-24 11:00
Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection
Sanofi SA (NASDAQ:SNY) secured two regulatory milestones this week, with European authorities approving Cenrifki for non-relapsing secondary progressive multiple sclerosis (nrSPMS) and Japanese regulators authorizing Wayrilz for persistent and chronic immune thrombocytopenia. Read Also: Sanofi Trial...
06-24 00:21
